<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Epigenetic changes play a role and cooperate with genetic alterations in the pathogenesis of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>We conducted a phase II multicenter study on the combination of the DNA-methyltransferase inhibitor <z:chebi fb="0" ids="2038">5-azacytidine</z:chebi> (5-AZA) and the <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase inhibitor <z:chebi fb="0" ids="39867">valproic acid</z:chebi> (VPA) in patients with higher risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>EXPERIMENTAL DESIGN: We enrolled 62 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (<z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts, 39 patients; <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts in transformation, 19 patients; and <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomanocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>), 4 patients) and an International Prognostic Scoring System (IPSS) rating of Intermediate-2 (42 patients) or high (20 patients) </plain></SENT>
<SENT sid="3" pm="."><plain>VPA was given to reach a plasma concentration of &gt;50 microg/mL, then 5-AZA was added s.c. at 75 mg/m(2) for 7 days in eight monthly cycles </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The median overall survival was 14.4 months </plain></SENT>
<SENT sid="5" pm="."><plain>At a median follow-up of 12 months (range, 0.7-21.0), the disease progressed in 20 patients, with 21% cumulative incidence of progression </plain></SENT>
<SENT sid="6" pm="."><plain>Of 26 patients who completed eight cycles, 30.7% obtained complete or partial remission, 15.4% had a major hematologic improvement, whereas 38.5% showed stable disease </plain></SENT>
<SENT sid="7" pm="."><plain>Drug-related toxicity was mild </plain></SENT>
<SENT sid="8" pm="."><plain>Favorable prognostic factors for survival were IPSS Intermediate-2 and plasma VPA of &gt; or =50 microg/mL (log rank = 0.013 and 0.007, respectively) </plain></SENT>
<SENT sid="9" pm="."><plain>Analysis of polymorphisms important for the metabolism of the drugs used in the trial showed that carriers of the CYP2C19*2 variant of <z:chebi fb="0" ids="38559">cytochrome P450</z:chebi> required higher VPA doses to achieve the target VPA plasma concentration of 50 microg/mL on day 1 of 5-AZA treatment (P = 0.0021) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: Our data show that the 5-AZA/VPA combination is active and safe in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with a poor prognosis </plain></SENT>
<SENT sid="11" pm="."><plain>Achievement of VPA therapeutic levels may indeed increase 5-AZA efficacy </plain></SENT>
</text></document>